Takeda and Frazier to launch HilleVax for norovirus vaccine development
The newly launched biopharma company will gain rights to the vaccine candidate in global markets, except Japan.
Infectious Diseases
FDA expands EUA for Lilly-Incyte’s baricitinib as Covid-19 monotherapy
In the initial EUA, baricitinib was authorised for use only with remdesivir for the treatment...
Pfizer records 92% growth in Q2 2021 revenue
For the full-year 2021, Pfizer increased revenue guidance to $78bn-$80bn, including about $33.5bn from Covid-19...
GSK and Vir enter supply deal with European Commission for Covid-19 drug
EU member states will be able to procure sotrovimab after emergency authorisation.
What could a vaccine patent waiver mean for pharma manufacturing?
Advocates of a patent waiver for Covid-19 vaccines say it would increase global vaccine production,...
Dyadic and Rubic to develop Covid-19 vaccines for African markets
Rubic will pay a licencing fee that is equal to a proportion of product sales or a vaccine fee on a per-dose basis to Dyadic.
Nothing to sneeze at: nasal sprays to tackle Covid-19
Pharmaceutical Technology takes a look at some of the nasal sprays in development for the treatment and prevention of Covid-19.
FDA approves GSK’s shingles vaccine for immunocompromised adults
The vaccine was first approved in the US in 2017 to prevent the disease in individuals aged 50 years or above.
Adagio and Biocon collaborate to develop antibody therapy for Covid-19
Biocon will obtain data from Adagio’s EUA submissions to pursue approval for the treatment in India and other emerging markets.
US acquires 200 million more doses of Pfizer-BioNTech’s Covid-19 vaccine
The companies previously agreed to supply 500 million doses of vaccine to the US Government for donation to 100 other nations.
Fighting India’s ‘black fungus’ epidemic
What exactly is black fungus, and what can be done to combat the rise of this condition alongside Covid-19? Abi Millar finds out.
